NCT07713901Enrolling by invitation
Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
Source: ClinicalTrials.gov · Last updated 4 Aug 2026
Brief summary (registry, in English)
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 93600000 (estimated)
- First submitted
- 15 Jul 2026
- Start date
- 31 Dec 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Thyroid cancer
- NCT number
- NCT07713901
What you commit to
- Study type: Observational
- Planned participants: 93600000
- From 31 Dec 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.
Who the study is looking for
- 18 years or older during the year of index (date of qualifying medication)
- In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1
- ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)
- No evidence of cohort qualifying medication during 12-month before the index date
- Reside in the US, including the District of Columbia (DC) during the study period
- No missing values for year of birth
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IQVIA Coordinator of this site? Confirm its status | Parsippany | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.